Life Sciences Tools and Services
Company Overview of PsychoGenics Inc.
PsychoGenics Inc. provides preclinical contract research and drug discovery services. The company offers various in vivo tests in the areas of animal models, anxiety, cognition, depression and sexual function, drug abuse liability, epilepsy, injury and pain, micro-dialysis, motor function, neurogenesis, neurological disorders, schizophrenia and mania, and other areas; and in vitro and ex vivo tests in the areas of electrophysiology, neurochemistry, quantitative western blots and quantitative RT-PCR and ELISA, and receptor occupancy. It also creates a range of drug candidates to address various CNS disorders, such as ADHD, cognitive impairment, depression, psychiatric and neurodegenerative di...
765 Old Saw Mill River Road
Tarrytown, NY 10591
Founded in 1999
Key Executives for PsychoGenics Inc.
Chief Executive Officer and President
Co-Founder, Chairman of the Scientific Advisory Board and Principal Scientific Advisor
Senior Vice President of Behavioral Pharmacology
Compensation as of Fiscal Year 2015.
PsychoGenics Inc. Key Developments
PsychoGenics Obtains License to Another Transgenic Mouse Model of a-Synucleinopathies
Aug 11 15
PsychoGenics announced that it has obtained a license from the University of California, San Diego School of Medicine to another a-synuclein transgenic mouse model known as Line 1, over-expressing human wild type a-synuclein under control of the MBP-promoter in oligodendrocytes. This model is a valuable tool to research the contribution of a-synuclein in the pathogenesis of multiple system atrophy (MSA). The Line 1 a-synuclein mouse model, expresses human wild type a-synuclein under control of the MBP promoter. These mice accumulate a-synuclein, including S129-phospho-synuclein, in oligodendrocytes from 3 months of age, and display neuropathological alterations including myelin loss, astrogliosis, and behavioral/motor deficits. These deficits progressively worsen with age. The increase in a-synuclein accumulation in oligodendrocytes contributes to mitochondrial dysfunction and oxidative injury, leading to neurodegeneration and recapitulates several of the key functional and neuropathological features seen in human MSA. PsychoGenics will now offer a broad suite of services in this model to biotech and pharmaceutical companies. Using its proprietary technologies, in particular NeuroCube®, PsychoGenics will provide a detailed analysis of the motor deficits and expects to be able to detect motor changes associated with MSA even earlier than previously reported based on its experience with other models. This would enable companies to explore prevention or early intervention treatment protocols. The Line 1 license is a worldwide license, in contrast to the licenses for the Line 61 and D-line mice previously licensed from UCSD. For Line 61 PsychoGenics has the right to promote and perform services anywhere in the world except UK, Germany, France and Austria; and for the D Line PsychoGenics has the right to promote and perform services anywhere in the world except UK, Germany, France, Austria and the USA. Accordingly, PsychoGenics does not promote or perform such services in those jurisdictions or otherwise where it is not able to lawfully practice.
PsychoGenics Receives License to the Cntnap2 Knockout Mouse Model from the Weizmann Institute
Jun 16 14
PsychoGenics Inc. announced that it has received a license to use the Cntnap2 knockout mouse from Yeda R&D Co. Ltd., the technology transfer company of the Weizmann Institute of Science. The CNTNAP2 gene encodes for Contactin Associated Protein 2 (Caspr2), a member of the neurexin family of cell recognition molecules. Mutations in this gene are associated with schizophrenia, autism, ADHD and language impairment. The Cntnap2 homozygous null mice were developed by Dr. Elior Peles. This model shows characteristics of Autism Spectrum Disorder (ASD) and ADHD such as deficits in a social test, hyperactivity in novel environments and changes in gait. Published reports describe reduced neonatal vocalizations, increased repetitive behavior and seizures, neuronal migration deficits with reduced interneuron number and asynchronous firing. In addition, pharmacological treatment with the antipsychotic risperidone improved repetitive behavior. Aspects of this phenotype were confirmed and expanded at PsychoGenics. This novel model of ASD promises to advance drug screening and development for ASD and associated disorders.
Similar Private Companies By Industry
Recent Private Companies Transactions